Patents by Inventor Kevin Foote

Kevin Foote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds
    Patent number: 8999997
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: April 7, 2015
    Assignee: AstraZeneca AB
    Inventors: Kevin Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • CHEMICAL COMPOUNDS
    Publication number: 20140018364
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: September 18, 2013
    Publication date: January 16, 2014
    Applicant: Astrazeneca AB
    Inventors: Kevin FOOTE, Johannes Wilhelmus, Maria NISSINK, Paul TURNER
  • QUINAZOLINE DERIVATIVES
    Publication number: 20100168143
    Abstract: The invention provided a compound of formula (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also processes for the preparation of such compounds, as well as pharmaceutical compositions containing them as active ingredient.
    Type: Application
    Filed: January 17, 2007
    Publication date: July 1, 2010
    Applicant: ASTRAZENECA AB
    Inventor: Michael Kevin Foote
  • 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)
    Publication number: 20080045517
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Application
    Filed: May 22, 2007
    Publication date: February 21, 2008
    Applicant: AstraZeneca AB
    Inventors: Kevin Foote, Zbigniew Matusiak, Alexander Dossetter, Jean Claude Arnould, Maryannick Lamorlette, Benedicte Delouvrie, Annie Hamon
  • Substituted 3-cyanoquinolines as MEK inhibitors
    Publication number: 20070213367
    Abstract: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
    Type: Application
    Filed: December 21, 2006
    Publication date: September 13, 2007
    Inventors: Laurent Francois Andre Hennequin, Keith Gibson, Kevin Foote
  • Substituted quinolines as antitumor agents
    Publication number: 20070021407
    Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt, pro-drug or solvate thereof.
    Type: Application
    Filed: March 14, 2006
    Publication date: January 25, 2007
    Inventors: Francis Boyle, Keith Gibson, Kevin Foote
  • 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)
    Publication number: 20060235067
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Application
    Filed: May 1, 2006
    Publication date: October 19, 2006
    Applicant: AstraZeneca AB
    Inventors: Kevin Foote, Zbigniew Matusiak, Alexander Dossetter, Jean Claude Arnould, Maryannick Lamorlette, Benedicte Delouvrie, Annie Hamon
  • Substituted 3-cyanoquinolines as mek inhibitors
    Publication number: 20060089382
    Abstract: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
    Type: Application
    Filed: July 4, 2003
    Publication date: April 27, 2006
    Inventors: Laurent Hennequin, Keith Gibson, Kevin Foote
  • 6H-thieno'2, 3-b!pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh)
    Publication number: 20060004082
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (1): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Application
    Filed: August 19, 2003
    Publication date: January 5, 2006
    Applicant: AstraZeneca
    Inventors: Kevin Foote, Zbigniew Matusiak, Alexander Dossetter, Jean Arnould, Maryannick Lamorlette, Benedicte Delouvrie, Annie Hamon
  • Quinzoline derivatives for use in the treatment of cancer
    Publication number: 20050250797
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
    Type: Application
    Filed: July 4, 2003
    Publication date: November 10, 2005
    Applicant: ASTRAZENECA AB
    Inventors: Laurent Hennequin, Keith Gibson, Kevin Foote
  • Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor
    Publication number: 20050209233
    Abstract: Compounds of formula (I): wherein: X is a group of formula (B): ?and R1, R2, R4, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being, are also described.
    Type: Application
    Filed: May 12, 2005
    Publication date: September 22, 2005
    Applicant: AstraZeneca AB
    Inventors: Michael Block, Kevin Foote
  • Carbazole derivatives and their use as npy5 receptor antagonists
    Publication number: 20050065157
    Abstract: The use of a compound of formula (I) in the manufacture of a medicament for the treatment, in a warm-blooded animal, of disorders mediated by the neuropeptide Y5 receptor: wherein: R1, R2, R3 and X1-X6 are as defined within or a pharmaceutically acceptable salt, prodrug or solvate thereof, is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.
    Type: Application
    Filed: September 9, 2002
    Publication date: March 24, 2005
    Inventors: Kevin Foote, Michael Block, Wayne Brailsford